Results 21 to 30 of about 3,703 (207)

TREC and KREC as prognostic markers of HIV infection and COVID-19

open access: diamondTuberculosis and Lung Diseases, 2022
In some infectious diseases, the number of T- and B-lymphocytes is significantly reduced which is associated with a high risk of the disease progression. The article reviews the effect of two RNA-containing viruses on the specific immune system: SARS-CoV-2 and HIV, as well as parameters of T- and B-cell neogenesis of TREC and KREC, which are markers of
E. I. Veselova   +4 more
openalex   +4 more sources

99P Quantitative indicators of TREC and KREC excision rings in malignant neoplasms [PDF]

open access: goldESMO Open, 2023
A.V. Sultanbaev   +8 more
openalex   +2 more sources

Evaluation of TREC/KREC levels in HIV-infected individuals

open access: diamondHIV Infection and Immunosuppressive Disorders
The aim of this study was to evaluate TREC and KREC levels in HIV-infected individuals.Materials and methods. The study material was whole blood samples obtained from HIV-infected individuals with less than one year of infection (n=50) and long-term patients with high viral load and virological failure of ART (n=50).
Yu. V. Ostankova   +3 more
openalex   +3 more sources

Harmonizing TREC Thresholds in Newborn Screening for SCID: Insights From Russian Validation Cohort. [PDF]

open access: yesJ Clin Lab Anal
Refining TREC cutoff values in newborn screening (NBS) for SCID: ROC analysis of a large testing cohort supports increasing the TREC threshold from 100 to 150–200 copies/105 cells, improving assay sensitivity and enabling earlier detection of SCID and other immunodeficiencies.
Marakhonov A   +14 more
europepmc   +2 more sources

A minimal physiologically-based pharmacokinetic modeling platform to predict intratumor exposure and receptor occupancy of an anti-LAG-3 monoclonal antibody. [PDF]

open access: yesCPT Pharmacometrics Syst Pharmacol
Abstract In oncology drug development, measuring drug concentrations at the tumor site and at the targeted receptor remains an ongoing challenge. Positron emission tomography (PET)‐imaging is a promising noninvasive method to quantify intratumor exposure of a radiolabeled drug (biodistribution data) and target saturation by treatment doses in vivo ...
Michelet R   +8 more
europepmc   +2 more sources

Differentiating Creatine and Phosphocreatine In Vivo Using 3 T 1H MR Spectroscopy. [PDF]

open access: yesMagn Reson Med
ABSTRACT Purpose Validation and improvements to the proton MR spectroscopic measurement of creatine and phosphocreatine in vivo at 3 T. Methods Spectral simulations were used to evaluate and explore the mitigation of LCModel fitting bias due to lineshape, signal‐to‐noise (SNR) and non‐metabolite backgrounds with a focus on phosphocreatine and the ...
Hurd RE   +9 more
europepmc   +2 more sources

UTILIZATION OF TREC AND KREC QUANTIFICATION FOR IMMUNE DEFICIENCIES RESEARCH IN MOLDOVA

open access: diamondBiological Markers in Fundamental and Clinical Medicine (collection of abstracts), 2019
UTILIZATION OF TREC AND KREC QUANTIFICATION FOR IMMUNE DEFICIENCIES RESEARCH IN ...
Alexandr DORIF   +3 more
openalex   +3 more sources

Five Years of Combined Newborn Screening Quantifying TREC and KREC in Switzerland

open access: hybridThe Journal of Allergy and Clinical Immunology: In Practice
Maarja Soomann   +19 more
  +5 more sources

Home - About - Disclaimer - Privacy